Skip to content
value.today

CB3 Life Sciences Ltd.

Total raised
$16 M
3 rounds on record
Latest round
$2 M
Oct 2021
First round on record
Oct 2018
Today
Private
No later event on record

Funding rounds

3 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of CB3 Life Sciences Ltd.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2023$1 MIssued in a merger or acquisitionUnder $2 million

CB3 Life Sciences Ltd.: Private sale, Jun 2023

Investors in this round

6 investors had bought by the notice of Jun 20, 2023: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$47,366
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Saskatchewan, Canada

People named in the notice

  • Brent Zettl · Executive Officer · Chief Executive Officer
  • Dr. Lionel Marks de Chabris · Executive Officer · Chief Medical Officer
  • John Hyshka · Executive Officer · Chief Financial Officer
  • Keith Carpenter · Executive Officer · Chief Strategy Officer
  • Garnette Weber · Director
  • John Knowles · Director
  • Richard Hoyt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Roth Capital Partners, LLC (CRD 15407) · Newport Beach, CaliforniaSold in CT, FL, MA, MO, NY
  • Stifel, Nicolaus & Company, Incorporated (CRD 793) · St. Louis, MissouriSold in CT, FL, MA, MO, NY
  • Haywood Securities (USA) Inc. (CRD 42072) · Vancouver, British Columbia, CanadaSold in CT, FL, MA, MO, NY

Remarks in the notice

  • On the amounts: “The total amount reflected in this section is based on a conversion rate of 1 USD = 1.343 CAD as of June 5 2023, and is reflective of the total offers and sales made in the U.S. only.”
  • On a merger: “The offering was conducted in conjunction with a reverse take-over transaction between the Issuer and Phoenix Canada Oil Company Limited.”

Signed by Brent Zettl, Ceo. Source: SEC Form D, newest notice filed Jun 20, 2023. Read the notice at the SEC.

equitySEC
Oct 2021$2 MNo. 3$2 to $10 million

CB3 Life Sciences Ltd.: Raise no. 3, Oct 2021

Investors in this round

2 investors had bought by the notice of Nov 3, 2021: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $5 M offered; $3 M still to sell
Smallest investment taken
$100,000
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Saskatchewan, Canada

People named in the notice

  • Brent Zettl · Executive Officer, Director · PRESIDENT and CEO
  • Keith Carpenter · Executive Officer · Chief Strategy and Investment Officer
  • Rob Harding · Executive Officer · Chief Financial Officer
  • Donald Ching · Director
  • Garnette Weber · Director
  • John Knowles · Director
  • Richard Hoyt · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Total Amount Sold is CAD 2,575,000 and was converted for this Form D filing to USD using the conversion rate on 11/3/21 of 1 USD = 1.24 CAD.”

Signed by Brent Zettl, President and CEO. Source: SEC Form D, newest notice filed Nov 3, 2021. Read the notice at the SEC.

debt, optionsSEC
Jul 2019$8 MIssued in a merger or acquisition$2 to $10 million

CB3 Life Sciences Ltd.: Private sale, Jul 2019

Investors in this round

47 investors had bought by the notice of Aug 13, 2019: 44 accredited, 3 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $18 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Saskatchewan, Canada

People named in the notice

  • Adam Darbellay · Executive Officer · Chief Financial Officer
  • Brent Zettl · Executive Officer, Director · President and Chief Executive Officer
  • Keith Carpenter · Executive Officer · Chief Strategy & Investment Officer
  • Larry Holbrook · Executive Officer · Chief Scientific Officer
  • Michelle Gursky · Executive Officer · VP Legal Affairs

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Additional Shares to be issued upon satisfaction of certain milestones post-merger. Original dollar amounts for offering were in CAD and were converted for this Form D filing to USD using a current conversion rate of 1 CAD = 0.76 USD.”
  • On a merger: “The Issuer has made this offering in connection with the acquisition of Revon Systems. Inc., pursuant to a Merger Agreement and Plan of Reorganization.”

Signed by Michelle Gursky, VP Legal Affairs. Source: SEC Form D, newest notice filed Aug 13, 2019. Read the notice at the SEC.

equitySEC
May 2019$2 MNo. 2$2 to $10 million

CB3 Life Sciences Ltd.: Raise no. 2, May 2019

Investors in this round

8 investors had bought by the notice of May 20, 2019: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $19 M offered; $16 M still to sell
Smallest investment taken
$37,125
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Saskatchewan, Canada

People named in the notice

  • Adam Darbellay · Executive Officer · CFO
  • Brent Zettl · Executive Officer, Director · President, CEO, Secretary
  • Keith Carpenter · Executive Officer · EVP, Strategy and M&A

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Original dollar amounts for offering were in CAD and were converted for this Form D filing to USD using a current conversion rate of 1 USD = 1.3468 CAD. The total amount sold is reflective of the amount sold in the United States.”

Signed by Brent Zettl, President. Source: SEC Form D, newest notice filed May 20, 2019. Read the notice at the SEC.

equitySEC
Oct 2018$12 MNo. 1$10 to $50 million

CB3 Life Sciences Ltd.: Raise no. 1, Oct 2018

Investors in this round

49 investors had bought by the notice of Oct 31, 2018: 49 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $19 M offered; $7 M still to sell
Smallest investment taken
$38,092
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Saskatchewan, Canada

People named in the notice

  • Allan Fowler · Executive Officer · CFO
  • Brent Zettl · Executive Officer, Director · President, CEO, Secretary
  • Keith Carpenter · Executive Officer · EVP, Strategy and M&A

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Original dollar amounts for offering were in CAD and were converted for this Form D filing to USD using a current conversion rate of 1 USD = 1.31260 CAD”

Signed by Brent Zettl, President. Source: SEC Form D, newest notice filed Oct 31, 2018. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • CB3 Life Sciences Ltd. chose not to state its revenue in its newest notice of a funding round (Jun 2023).

    SEC Form D · Jun 2023

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jun 2023

That is all the official record says: CB3 Life Sciences Ltd. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of CB3 Life Sciences Ltd. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 49 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by CB3 Life Sciences Ltd.
NameRoleNamed in
Brent ZettlChief Executive OfficerJun 2023
Dr. Lionel Marks de ChabrisChief Medical OfficerJun 2023
John HyshkaChief Financial OfficerJun 2023
Keith CarpenterChief Strategy OfficerJun 2023
Rob HardingChief Financial OfficerNov 2021
Adam DarbellayChief Financial OfficerAug 2019
Larry HolbrookChief Scientific OfficerAug 2019
Michelle GurskyVP Legal AffairsAug 2019
Allan FowlerCFOOct 2018
Garnette WeberDirectorJun 2023
John KnowlesDirectorJun 2023
Richard HoytDirectorJun 2023
Brent ZettlPRESIDENT and CEONov 2021
Donald ChingDirectorNov 2021